Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study.

Background: To evaluate the role of the novel quantitative imaging biomarker (QIB) SUV of F-FDG uptake extracted from early F-FDG-PET/CT scan at 4 weeks for the detection of immune-related adverse events (rAE) in a cohort of patients with metastatic melanoma (mM) patients receiving immune-checkpoint inhibitors (ICI).

Patients And Methods: In this prospective non-interventional, one-centre clinical study, patients with mM, receiving ICI treatment, were regularly followed by F-FDG PET/CT. Patients were scanned at baseline, early point at week four (W4), week sixteen (W16) and week thirty-two (W32) after ICI initiation.

Detection performance and prognostic value of initial bone marrow involvement in diffuse large B-cell lymphoma: a single centre F-FDG PET/CT and bone marrow biopsy evaluation study.

Background: Detection of bone marrow involvement (BMI) in diffuse large B-cell lymphoma (DLBCL) typically relies on invasive bone marrow biopsy (BMB) that faces procedure limitations, while F-FDG PET/CT imaging offers a noninvasive alternative. The present study assesses the performance of F-FDG PET/CT in DLBCL BMI detection, its agreement with BMB, and the impact of BMI on survival outcomes.

Patients And Methods: This retrospective study analyzes baseline F-FDG PET/CT and BMB findings in145 stage II-IV DLBCL patients, evaluating both performance of the two diagnostic procedures and the impact of BMI on survival.

The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers.

The evaluation of treatment response remains a challenge in glioma cases because the neuro oncological therapy can lead to the development of treatment-related changes (TRC) that mimic true progression (TP). Positron emission tomography (PET) using O-(2-[F] fluoroethyl-)-L-tyrosine (F-FET) has been shown to be a useful tool for detecting TRC and TP. We assessed the diagnostic performance of different F-FET PET segmentation approaches and different imaging biomarkers for differentiation between late TRC and TP in glioma patients.

Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.

Purpose: To develop quantitative molecular imaging biomarkers of immune-related adverse event (irAE) development in malignant melanoma (MM) patients receiving immune-checkpoint inhibitors (ICI) imaged with F-FDG PET/CT.

Methods: F-FDG PET/CT images of 58 MM patients treated with anti-PD-1 or anti-CTLA-4 ICI were retrospectively analyzed for indication of irAE. Three target organs, most commonly affected by irAE, were considered: bowel, lung, and thyroid.